Arkolith/Insider Trading/VNDA/Form 4

Birznieks Gunther

SVP, Business DevelopmentVanda Pharmaceuticals Inc. (VNDA) · full profile →Form 4 · filed Mar 4, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$351K
Net Open-Market Flow
-$351K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 2, 2026Sell(S)42K$8.27$351K494K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001702031-26-000002) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML